AU2003259145A8 - Treatment for dry eye syndrome - Google Patents

Treatment for dry eye syndrome

Info

Publication number
AU2003259145A8
AU2003259145A8 AU2003259145A AU2003259145A AU2003259145A8 AU 2003259145 A8 AU2003259145 A8 AU 2003259145A8 AU 2003259145 A AU2003259145 A AU 2003259145A AU 2003259145 A AU2003259145 A AU 2003259145A AU 2003259145 A8 AU2003259145 A8 AU 2003259145A8
Authority
AU
Australia
Prior art keywords
treatment
dry eye
eye syndrome
syndrome
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259145A
Other versions
AU2003259145A1 (en
Inventor
Spencer P Thornton
Ellen Troyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003259145A1 publication Critical patent/AU2003259145A1/en
Publication of AU2003259145A8 publication Critical patent/AU2003259145A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003259145A 2002-07-17 2003-07-17 Treatment for dry eye syndrome Abandoned AU2003259145A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39622202P 2002-07-17 2002-07-17
US60/396,222 2002-07-17
PCT/US2003/022297 WO2004006801A2 (en) 2002-07-17 2003-07-17 Treatment for dry eye syndrome

Publications (2)

Publication Number Publication Date
AU2003259145A1 AU2003259145A1 (en) 2004-02-02
AU2003259145A8 true AU2003259145A8 (en) 2004-02-02

Family

ID=30115988

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259145A Abandoned AU2003259145A1 (en) 2002-07-17 2003-07-17 Treatment for dry eye syndrome

Country Status (2)

Country Link
AU (1) AU2003259145A1 (en)
WO (1) WO2004006801A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009522A1 (en) * 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
BRPI0612596A2 (en) * 2005-07-01 2010-11-23 Sigma Tau Ind Farmaceuti use of l-carnitine or alkanoyl-l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops
US8349317B2 (en) * 2005-07-08 2013-01-08 Sigma-Tau Industrie Farmaceutiche Riunite Spa Use of L-carnitine or an alkanoyl L-carnitine, for the preparation of a dietary supplement or medicament for the treatment of corneal disease
WO2007032997A1 (en) * 2005-09-13 2007-03-22 Bausch & Lomb Incorporated Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye
US7638142B2 (en) * 2005-10-12 2009-12-29 Vitamin Science, Inc. Therapeutic composition for the treatment of dry eye syndrome
EP2101725A1 (en) * 2006-12-14 2009-09-23 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
JP6665099B2 (en) * 2014-08-29 2020-03-13 わかもと製薬株式会社 Lactic acid bacteria-containing composition
MX2017016991A (en) * 2017-12-20 2019-06-21 Centro De Retina Medica Y Quirurgica S C Oral administration formulation of blueberry extract as a coadjuvant for preserving the health of human precorneal film.
NO345574B1 (en) * 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
EP0861088A1 (en) * 1995-11-14 1998-09-02 Xoma Corporation Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
AU1295200A (en) * 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
US6537581B2 (en) * 2000-06-01 2003-03-25 Theralife, Inc. Compositions and methods for treating eye discomfort
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome

Also Published As

Publication number Publication date
WO2004006801A3 (en) 2004-06-10
WO2004006801A2 (en) 2004-01-22
AU2003259145A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
EP1689485A4 (en) Cardioelectromagnetic treatment
IL168052A0 (en) Drying process
AU2003237159A8 (en) Treatment for phenylketonuria
AU2003259145A8 (en) Treatment for dry eye syndrome
GB0326486D0 (en) Combination treatment
GB0312407D0 (en) Treatment
EP1620117A4 (en) Improved antitumoral treatments
IL165242A0 (en) Treatment for diabetes
GB0223570D0 (en) Surface treatment
GB0225273D0 (en) Polymer treatment
AU2003285266A1 (en) Textile treatment agent
GB0221574D0 (en) Treatments
GB0209167D0 (en) Drying apparatus
GB0221157D0 (en) Novel treatment
GB0209135D0 (en) Fiber treatment composition
GB0327493D0 (en) Treatment medicament
AU2003248679A8 (en) Treating disease using radium-225
GB0225520D0 (en) Drying process
GB0212821D0 (en) Eyewash
AU2003215255A8 (en) Novel treatment for pathologies associated with oxidative damage
GB0220820D0 (en) Treatment
GB0213493D0 (en) Treatment
GB0203967D0 (en) Pop-stars fantasy league
GB0218818D0 (en) Novel treatment
GB0702858D0 (en) Dressinf for tissue treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase